Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MutHER: Neratinib in HER2-mutant MBC
NCT01670877Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2012
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Washington University School of Medicine. Started Dec 2012; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01670877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670877.